Dr. Ursula A. Matulonis, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 162
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Albany Medical College of Union University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 72597
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Beth Israel Deaconess Medical Center Boston, MA
- North Shore Medical Center - Salem, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 162
- Services billed
- 469
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 196 | 103 |
| Established patient office or other outpatient visit, 30-39 minutes | 78 | 51 |
| Established patient office or other outpatient visit, 10-19 minutes | 64 | 48 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $22,000 in total to this clinician.
| Aadi Bioscience, Inc. | $9,000 |
|---|---|
| GlaxoSmithKline, LLC. | $8,400 |
| Merck Sharp & Dohme LLC | $4,480 |
| Daiichi Sankyo Inc. | $77.08 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Consulting Fee | $20,680 |
|---|---|
| Travel and Lodging | $1,000 |
| Food and Beverage | $277 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aadi Bioscience, Inc. Aug 5, 2025 | Consulting Fee Fyarro · Cancer | $9,000 |
| GlaxoSmithKline, LLC. Apr 16, 2025 | Consulting Fee | $7,200 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee | $4,480 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $417 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $390 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $193 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $72,103 in research payments for these studies, mostly to the institutions running them.
- (VELA) Study of BLU-222 in Advanced Solid Tumors
Sanofi US Services Inc. · Terminated · NCT05252416 - Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie Inc. · Active, not recruiting · NCT05456685 - A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
Blueprint Medicines Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.